参考文献/References:
[1] Lee C,Zeng J,Drew BG,et al.The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance[J].Cell Metab,2015,21(3):443-454.DOI:10.1016/j.cmet.2015.02.009.
[2] Entezari M,Hashemi D,Taheriazam A,et al.AMPK signaling in diabetes mellitus,insulin resistance and diabetic complications:a pre-clinical and clinical investigation[J].Biomed Pharmacother,2022,146:112563.DOI:10.1016/j.biopha.2021.112563.
[3] Ramanjaneya M,Bettahi I,Jerobin J,et al.Mitochondrial-derived peptides are down regulated in diabetes subjects[J].Front Endocrinol(Lausanne),2019,10:331.DOI:10.3389/fendo.2019.00331.
[4] Kim SJ,Miller B,Mehta HH,et al.The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity[J].Physiol Rep,2019,7(13):e14171.DOI:10.14814/phy2.14171.
[5] Blake R,Trounce IA.Mitochondrial dysfunction and complications associated with diabetes[J].Biochim Biophys Acta,2014,1840(4):1404-1412.DOI:10.1016/j.bbagen.2013.11.007.
[6] Bernard JR,Reeder DW,Herr HJ,et al.High-fat feeding effects on components of the CAP/Cbl signaling cascade in Sprague-Dawley rat skeletal muscle[J].Metabolism,2006,55(2):203-212.DOI:10.1016/j.metabol.2005.08.013.
[7] Kong BS,Min SH,Lee C,et al.Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes[J].Cell Rep,2021,36(4):109447.DOI:10.1016/j.celrep.2021.109447.
[8] Zheng Y,Wei Z,Wang T.MOTS-c:a promising mitochondrial-derived peptide for therapeutic exploitation[J].Front Endocrinol(Lausanne),2023,14:1120533.DOI:10.3389/fendo.2023.1120533.
[9] Ziqubu K,Dludla PV,Mthembu SXH,et al.An insight into brown/beige adipose tissue whitening,a metabolic complication of obesity with the multifactorial origin[J].Front Endocrinol(Lausanne),2023,14:1114767.DOI:10.3389/fendo.2023.1114767.
[10] Lu H,Tang S,Xue C,et al.Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation[J].Int J Mol Sci,2019,20(10):2456.DOI:10.3390/ijms20102456.
[11] Lu H,Wei M,Zhai Y,et al.MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction[J].J Mol Med(Berl),2019,97(4):473-485.DOI:10.1007/s00109-018-01738-w.
[12] Herzig S,Shaw RJ.AMPK:guardian of metabolism and mitochondrial homeostasis[J].Nat Rev Mol Cell Biol,2018,19(2):121-135.DOI:10.1038/nrm.2017.95.
[13] Li Q,Lu H,Hu G,et al.Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c[J].Biochem Biophys Res Commun,2019,513(2):439-445.DOI:10.1016/j.bbrc.2019.03.194.
[14] Friedman SL,Neuschwander-Tetri BA,Rinella M,et al.Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.DOI:10.1038/s41591-018-0104-9.
[15] 孟祥祺,苑姗姗,戴红艳,等.冠心病患者血清中MOTS-c水平及其与冠状动脉病变严重程度的关系[J].临床心血管病杂志,2020,36(3):228-232.DOI:10.13201/j.issn.1001-1439.2020.03.008.
[16] Qin Q,Delrio S,Wan J,et al.Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction[J].Int J Cardiol,2018,254:23-27.DOI:10.1016/j.ijcard.2017.12.001.
[17] Kim KH,Son JM,Benayoun BA,et al.The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress[J].Cell Metab,2018,28(3):516-524.e7.DOI:10.1016/j.cmet.2018.06.008.
[18] Montarello NJ,Nguyen MT,Wong DTL,et al.Inflammation in coronary atherosclerosis and its therapeutic implications[J].Cardiovasc Drugs Ther,2022,36(2):347-362.DOI:10.1007/s10557-020-07106-6.
[19] 崔敏萱,王文文,向安,等.线粒体来源肽MOTS-c通过抑制促炎性因子分泌改善脓毒症小鼠生存率[J].现代生物医学进展,2019,19(15):2839-2844.DOI:10.13241/j.cnki.pmb.2019.15.008.
[20] Wan W,Zhang L,Lin Y,et al.Mitochondria-derived peptide MOTS-c:effects and mechanisms related to stress, metabolism and aging[J].J Transl Med,2023,21(1):36.DOI:10.1186/s12967-023-03885-2.
[21] Yahara Y,Nguyen T,Ishikawa K,et al.The origins and roles of osteoclasts in bone development,homeostasis and repair[J].Development,2022,149(8):dev199908.DOI:10.1242/dev.199908.
[22] Ming W,Lu G,Xin S,et al.Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation[J].Biochem Biophys Res Commun,2016,476(4):412-419.DOI:10.1016/j.bbrc.2016.05.135.
[23] Che N,Qiu W,Wang JK,et al.MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway[J].Eur Rev Med Pharmacol Sci,2019,23(8):3183-3189.DOI:10.26355/eurrev_201904_17676.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(01):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(01):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(01):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(01):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(01):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(01):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(01):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]